COPN Stock Overview
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 5/6 |
Past Performance | 1/6 |
Financial Health | 5/6 |
Dividends | 2/6 |
Cosmo Pharmaceuticals N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF73.40 |
52 Week High | CHF73.70 |
52 Week Low | CHF33.70 |
Beta | 1.19 |
1 Month Change | 11.04% |
3 Month Change | 17.82% |
1 Year Change | 34.19% |
3 Year Change | -18.90% |
5 Year Change | -23.70% |
Change since IPO | 229.15% |
Recent News & Updates
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Recent updates
Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture
Mar 28Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher
Mar 26Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear
Dec 01Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Jul 29We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt
Nov 24Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals
Mar 31These 4 Measures Indicate That Cosmo Pharmaceuticals (VTX:COPN) Is Using Debt Reasonably Well
Aug 02Increases to CEO Compensation Might Be Put On Hold For Now at Cosmo Pharmaceuticals N.V. (VTX:COPN)
May 20Cosmo Pharmaceuticals (VTX:COPN) Seems To Use Debt Quite Sensibly
Apr 03When Can We Expect A Profit From Cosmo Pharmaceuticals N.V. (VTX:COPN)?
Mar 07What Kind Of Investors Own Most Of Cosmo Pharmaceuticals N.V. (VTX:COPN)?
Feb 01Cosmo Pharmaceuticals'(VTX:COPN) Share Price Is Down 47% Over The Past Five Years.
Dec 27Shareholder Returns
COPN | CH Pharmaceuticals | CH Market | |
---|---|---|---|
7D | 4.1% | -0.9% | -0.9% |
1Y | 34.2% | -13.1% | -4.0% |
Return vs Industry: COPN exceeded the Swiss Pharmaceuticals industry which returned -13.1% over the past year.
Return vs Market: COPN exceeded the Swiss Market which returned -4% over the past year.
Price Volatility
COPN volatility | |
---|---|
COPN Average Weekly Movement | 3.9% |
Pharmaceuticals Industry Average Movement | 3.3% |
Market Average Movement | 3.5% |
10% most volatile stocks in CH Market | 7.4% |
10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: COPN has not had significant price volatility in the past 3 months.
Volatility Over Time: COPN's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 319 | Alessandro Della Cha | www.cosmopharma.com |
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology, endoscopy, dermatology, and healthtech worldwide. The company offers Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Lumeblue (methylene blue MMX), a diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy; Uceris/Cortiment, an oral tablet formulation which delivers budesonide directly to the lumen of the colon; Aemcolo/Relafalk, a GI antibiotic with MMX® technology and is approved for the treatment of travellers’ diarrhoea; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Eleview, a medical device, which enables the safer and faster removal of colonic lesions; and GI Genius, a system that uses artificial intelligence to detect colorectal polyps during colonoscopy. It is also in the development of Breezula (clascoterone), a novel androgen receptor inhibitor that targets androgen receptors in the scalp, currently expecting phase III trials; Rifamycin SV MMX – IBS-D, a formulation to treat colonic infections and irritable bowel syndrome with diarrhoea, currently completed phase II proof of concept clinical trials; CB-03-10 (cortexolone 17 -valerate-21-propionate), an oral androgen receptor antagonist for treatment solid tumors, currently under phase I studies; and CB-01-33 (colesevelam) for the treatment of bile acid diarrhea, currently under preclinical studies.
Cosmo Pharmaceuticals N.V. Fundamentals Summary
COPN fundamental statistics | |
---|---|
Market cap | CHF1.18b |
Earnings (TTM) | CHF1.11m |
Revenue (TTM) | CHF94.01m |
1,057x
P/E Ratio12.5x
P/S RatioIs COPN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COPN income statement (TTM) | |
---|---|
Revenue | €96.72m |
Cost of Revenue | €39.34m |
Gross Profit | €57.38m |
Other Expenses | €56.24m |
Earnings | €1.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | 0.071 |
Gross Margin | 59.33% |
Net Profit Margin | 1.19% |
Debt/Equity Ratio | 0.1% |
How did COPN perform over the long term?
See historical performance and comparison